National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 77876 [2024-21737]
Download as PDF
<![CDATA[
77876
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
Publications: Protective human
monoclonal antibodies target conserved
sites of vulnerability on the underside of
influenza virus neuraminidase.
Lederhofer, Julia et al. Immunity,
Volume 57, Issue 3, 574–586.e7.
Intellectual Property: PCT/US2023/
071194 filed 28 July 2023 (NIH Ref. No.
E–177–2022).
Licensing Contact: To license this
technology, please contact Haiqing Li at
240–627–3708, or lihai@mail.nih.gov,
and reference E–177–2022.
Dated: September 18, 2024.
Christopher M. Kornak,
Acting Deputy Director, Technology Transfer
and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases.
[FR Doc. 2024–21742 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity review.
Date: October 29, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, NIDDK
Democracy II, Suite 7000A, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, National Institute
of Diabetes and Digestive and Kidney,
National Institute of Health, 6707 Democracy
Boulevard, Rm. 7353, Bethesda, MD 20892–
2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
VerDate Sep<11>2014
18:07 Sep 23, 2024
Jkt 262001
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–21737 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: New: The Center for
Substance Abuse Prevention Online
Reporting Tool and Grant Programmatic
Progress Report to replace Division of
State Programs—Management Reporting
Tool (DSP–MRT) (OMB No. 0930–0354).
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA), Center for Substance Abuse
Prevention (CSAP) is requesting
approval from the Office of Management
and Budget (OMB) to monitor CSAP
discretionary grant programs through
administration of a suite of data
collection instruments for grant
compliance and programmatic
performance monitoring.
This package describes the data
collection activities and proposed
instruments. Grant compliance
monitoring will be conducted via a
single data collection instrument to be
completed by all CSAP discretionary
grant recipients. Programmatic
performance monitoring will be
conducted via a suite of data collection
instruments with each instrument
tailored to a specific CSAP discretionary
program. This request for data collection
will replace OMB No. 0930–0354:
Division of State Programs—
Management Reporting Tool.
CSAP intends to monitor six grant
programs through this data collection
effort:
• Strategic Prevention Framework—
Partnerships for Success (SPF–PFS): The
purpose of the SPF–PFS program is to
help reduce the onset and progression of
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
substance misuse and its related
problems by supporting the
development and delivery of state and
community substance misuse
prevention and mental health
promotion services. This program is
intended to promote substance use
prevention throughout a state
jurisdiction for individuals and families
by building and expanding the capacity
of local community prevention
providers to implement evidence-based
programs. In addition, the program is
intended to expand and strengthen the
capacity of local community prevention
providers to implement evidence-based
prevention programs. With this
program, SAMHSA aims to strengthen
state and community level prevention
capacity to identify and address local
substance use prevention concerns,
such as underage drinking, marijuana,
tobacco, electronic cigarettes, opioids,
methamphetamine, and heroin.
• Sober Truth on Preventing
Underage Drinking (STOP Act): The
purpose of this program is to prevent
and reduce alcohol use among youth
and young adults ages 12–20 in
communities throughout the United
States through evidence-based
screening, programs and curricula, brief
intervention strategies, consistent policy
enforcement, and environmental
changes that limit underage access to
alcohol as authorized by 42 U.S.C.
290bb–25b. The program aims to: (1)
address norms regarding alcohol use by
youth, (2) reduce opportunities for
underage drinking, (3) create changes in
underage drinking enforcement efforts,
(4) address penalties for underage use,
and/or (5) reduce negative consequences
associated with underage drinking.
• Strategic Prevention Framework for
Prescription Drugs (SPF Rx): The
purpose of the SPF Rx grant program is
to provide resources to help prevent and
address prescription drug misuse within
a State or locality. The program is
designed to raise awareness about the
dangers of sharing medications as well
as the risks of fake or counterfeit pills
purchased over social media or other
unknown sources, and work with
pharmaceutical and medical
communities on the risks of
overprescribing. Whether addressed at
the state level or by an informed
community-based organization, the SPF
Rx program will raise community
awareness and bring prescription
substance misuse prevention activities
and education to schools, communities,
parents, prescribers, and their patients.
In addition, grant recipients will be
required to track reductions in opioid
related overdoses and incorporate
relevant prescription and overdose data
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 89, Number 185 (Tuesday, September 24, 2024)]
[Notices]
[Page 77876]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21737]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity
review.
Date: October 29, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NIDDK Democracy II, Suite
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Michele L. Barnard, Ph.D., Scientific Review
Officer, National Institute of Diabetes and Digestive and Kidney,
National Institute of Health, 6707 Democracy Boulevard, Rm. 7353,
Bethesda, MD 20892-2542, (301) 594-8898,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-21737 Filed 9-23-24; 8:45 am]
BILLING CODE 4140-01-P
